Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CABARESC: budesonide prophylaxis for cabazitaxel-induced diarrhea in metastatic castration-resistant prostate cancer
NL-OMON41486Phase 2Active, not recruiting
- Sponsor
- Erasmus MC
- Start
- Dec 2011
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of budesonide and cabazitaxel in prostate cancer (PCa) (2 arms), sponsored by Erasmus MC. Primary endpoint: Incidence of cabazitaxel-induced diarrhea. Started Dec 2011; status: active, not recruiting.
02
Drugs
budesonidecabazitaxel
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NL-OMON41486.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41486.